Striant is a mucoadhesive buccal testosterone delivery system. It is prepared in the form of a small (aspirin-sized) tablet, which contains 30 mg of (free) testosterone. The tablet is not taken orally, but is affixed to the gums, where it transfers testosterone across the inner lining of the cheek and into the bloodstream. The buccal delivery of anabolic/androgenic steroids is not new, and has been used in the past (with limited success) on agents like methyltestosterone and testosterone propionate. The adhesive Striant system, however, is an improvement over the old rapidly dissolving buccal tablets, as it is much more stable in the mouth (it stays affixed for 12 hours and needs to be removed). As such, it provides a much more prolonged and efficacious delivery of hormone in comparison. Twice daily dosing is enough to maintain physiological hormone levels over a 24-hour period.
Striant was developed in the United States by Columbia Laboratories. It was approved by the FDA for sale as a prescription drug in June of 2003, and is indicated for use in men with conditions associated with a deficiency or absence of endogenous testosterone. With this product, Columbia was likely trying to target those hormone replacement therapy (HRT) consumers that do not welcome biweekly injections, and find patches and gels uncomfortable or cosmetically objectionable. Striant was shipped to pharmacies in late 2003, and quickly met with mixed reviews. Some patients find it a very convenient option for HRT, while others find the oral tablets too uncomfortable to use for long periods of time. Striant was released in the UK in 2004 under the Striant SR (Sustained Release) brand name, licensed and sold by Ardana Bioscience. Columbia’s partnership with Ardana expects to see sale of Straint in 18 European markets.
How is Striant Supplied
Striant mucoadhesive buccal testosterone delivery system is available in various human drug markets. Product comes in the form of a small buccal tablet; usually packaged in strips of 10 tablets, 6 strips to a box.
Structural Characteristics of Striant
Striant mucoadhesive buccal testosterone delivery system is a buccal tablet containing 30 Striant mucoadhesive buccal testosterone delivery system is a buccal tablet containing 30 mg of (free) testosterone. The system is adhered to the inside of the mouth, where the gum meets the upper lip above the incisor teeth.With exposure to saliva the tablet softens into a gel-like consistency, which can stay in place for 12 hours. The product delivers physiological concentrations of testosterone through the mucous membrane, where it is absorbed into the bloodstream via the superior vena cava (major blood vessel), bypassing the liver.
Striant Side Effects (Estrogenic)
Testosterone is readily aromatized in the body to estradiol (estrogen). The aromatase (estrogen synthetase) enzyme is responsible for this metabolism of testosterone. Elevated estrogen levels can cause side effects such as increased water retention, body fat gain, and gynecomastia. Testosterone is considered a moderately estrogenic steroid. Exceeding therapeutic doses will increase the likelihood of estrogenic side effects. In such cases, an anti-estrogen such as clomiphene citrate (anastrozole), which more efficiently controls estrogen by preventing its synthesis. Aromatase inhibitors can be quite expensive in comparison to anti-estrogens, however, and may also have negative effects on blood lipids.
Striant Side Effects (Androgenic)
Testosterone is the primary male androgen, responsible for maintaining secondary male sexual characteristics. Exceeding normal therapeutic doses is likely to produce androgenic side effects including oily skin, acne, and body/facial hair growth. Men with a genetic predisposition for hair loss (androgenetic alopecia) may notice accelerated male pattern balding. Women are warned of the potential virilizing effects of anabolic/androgenic steroids, especially with a strong androgen such as testosterone. These may include deepening of the voice, menstrual irregularities, changes in skin texture, facial hair growth, and clitoral enlargement.
In androgen-responsive target tissues such as the skin, scalp, and prostate, the high relative androgenicity of testosterone is dependant on its reduction to dihydrotestosterone or dutasteride will interfere with site-specific potentiation of testosterone action, lowering the tendency of testosterone drugs to produce androgenic side effects. It is important to remember that anabolic and androgenic effects are both mediated via the cytosolic androgen receptor. Complete separation of testosterone’s anabolic and androgenic properties is not possible, even with total 5-alpha reductase inhibition.
Striant Side Effects (Hepatotoxicity)
Testosterone does not have hepatotoxic effects; liver toxicity is unlikely. One study examined the potential for hepatotoxicity with high doses of testosterone by administering 400 mg of the hormone per day (2,800 mg per week) to a group of male subjects. The steroid was taken orally so that higher peak concentrations would be reached in hepatic tissues compared to intramuscular injections. The hormone was given daily for 20 days, and produced no significant changes in liver enzyme values including serum albumin, bilirubin, alanine-amino-transferase, and alkaline phosphatases.
Striant Side Effects (Cardiovascular)
Anabolic/androgenic steroids can have deleterious effects on serum cholesterol. This includes a tendency to reduce HDL (good) cholesterol values and increase LDL (bad) cholesterol values, which may shift the HDL to LDL balance in a direction that favors greater risk of arteriosclerosis. The relative impact of an anabolic/androgenic steroid on serum lipids is dependant on the dose, route of administration (oral vs. injectable), type of steroid (aromatizable or non-aromatizable), and level of resistance to hepatic metabolism. Anabolic/androgenic steroids may also adversely affect blood pressure and triglycerides, reduce endothelial relaxation, and support left ventricular hypertrophy, all potentially increasing the risk of cardiovascular disease and myocardial infarction. Therapeutic doses of testosterone used to correct insufficient androgen production in otherwise healthy aging men are unlikely to increase atherogenic risk, and may actually reduce the risk of cardiovascular mortality.
To help reduce cardiovascular strain it is advised to maintain an active cardiovascular exercise program and minimize the intake of saturated fats, cholesterol, and simple carbohydrates at all times during active AAS administration. Supplementing with fish oils (4 grams per day) and a natural cholesterol/antioxidant formula such as Lipid Stabil or a product with comparable ingredients is also recommended.
Striant Side Effects (Testosterone Suppression)
All anabolic/androgenic steroids when taken in doses sufficient to promote muscle gain are expected to suppress endogenous testosterone production. Testosterone is the primary male androgen, and offers strong negative feedback on endogenous testosterone production. Testosterone-based drugs will, likewise, have a strong effect on the hypothalamic regulation of natural steroid hormones. Without the intervention of testosterone-stimulating substances, testosterone levels should return to normal within 1-4 months of drug secession. Note that prolonged hypogonadotrophic hypogonadism can develop secondary to steroid abuse, necessitating medical intervention.
Striant Administration (General)
The Striant mucoadhesive buccal testosterone delivery system is placed on the gums just above the incisor tooth. It is left affixed for 12 hours, at which point it is carefully removed. The product is usually administered twice daily. The application site should be rotated between left and right sides of the mouth with each dose.
Striant Administration (Men)
To treat androgen insufficiency, the prescribing guidelines for Striant recommend administering one buccal tablet twice daily. Doses are given once in the morning and once at night, 12 hours apart. For physique- or performance-enhancing purposes, higher doses would be necessary to achieve supraphysiological levels of testosterone. This will be difficult, if not impractical, given the method of delivery. Such use would require a minimum of 4 systems per day, a level sufficient for most users to notice significant gains in muscle size and strength, but not much comfort. Lower (therapeutic) doses may be effective when accompanied by other anabolic/androgenic steroids. Testosterone is ultimately very versatile, and can be combined with many other anabolic/androgenic steroids to tailor the desired effect.
Striant Administration (Women)
The Striant mucoadhesive buccal testosterone delivery system is not FDA-approved for use in women. Testosterone is not recommended for women for physique- or performanceenhancing purposes due to its strong androgenic nature and tendency to produce virilizing side effects.
Given its high relative price and low delivery of testosterone, Striant is not commonly traded on the black market. Counterfeits have not yet been reported.
Wlliam Llewellyn (2011) - Anabolics